A biopharmaceutical SME from Turkey is developing a Eurostars proposal to profile MEIS oncogene in patient derived tumor organoids and xenografts models and outline the potential of the first-in-class MEIS inhibitors.
Partners sought: A company and a university research group with expertise in ex vivo cancer PDX models, organoids, in vivo efficacy in animal models and diagnostic development are sought.
Solicite mayor información mencionando el código de referencia desde aquí